Skip to main content

7 Result(s)

within Oronzo Brunetti Remove this filter Biomedicine, general Remove this filter

and

  1. No Access

    Article

    Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study

    The TOPAZ-1 phase III trial reported a survival benefit with the anti-programmed cell death ligand 1 (anti-PD-L1) durvalumab in combination with gemcitabine and cisplatin in patients with advanced biliary trac...

    Margherita Rimini, Gianluca Masi, Sara Lonardi, Federico Nichetti… in Targeted Oncology (2024)

  2. Article

    Correction to: Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma

    An Online First version of this article was made available online at https://springer.longhoe.net/article/10.1007/s11523-020-00757-3 on 12 October 2020. Errors were s...

    Giulia Orsi, Francesco Tovoli, Vincenzo Dadduzio, Caterina Vivaldi… in Targeted Oncology (2020)

    Download PDF (500 KB) View Article

  3. No Access

    Article

    Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma

    Inflammation is a long-established hallmark of liver fibrosis and carcinogenesis. Eosinophils are emerging as crucial components of the inflammatory process influencing cancer development. The role of blood eo...

    Giulia Orsi, Francesco Tovoli, Vincenzo Dadduzio, Caterina Vivaldi… in Targeted Oncology (2020)

  4. No Access

    Article

    Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma

    Sorafenib is recommended for the treatment of advanced-stage hepatocellular carcinoma (HCC). Nonetheless, it is expensive, effective in few patients, and may cause significant adverse effects. Therefore, accur...

    Giovan Giuseppe Di Costanzo, Andrea Casadei Gardini, Giorgia Marisi… in Targeted Oncology (2017)

  5. No Access

    Article

    The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following?

    The encouraging results in immunotherapy for melanoma also led the way for translational and clinical research about immune-related mechanisms possibly relevant for gastrointestinal tumours. It is in fact now ...

    Marco Puzzoni, Nicola Silvestris, Francesco Leone, Riccardo Giampieri… in Targeted Oncology (2016)

  6. Article

    Open Access

    Everolimus restrains the paracrine pro-osteoclast activity of breast cancer cells

    Breast cancer (BC) cells secrete soluble factors that accelerate osteoclast (OC) differentiation, leading to the formation of osteolytic bone metastases. In the BOLERO-2 trial, BC patients with bone involvemen...

    Valeria Simone, Sabino Ciavarella, Oronzo Brunetti, Annalisa Savonarola… in BMC Cancer (2015)

    Download PDF (4630 KB) View Article

  7. No Access

    Article

    Bone metastases in hepatocellular carcinoma: an emerging issue

    The nature and the characteristics of bone metastases (BMs) in hepatocellular carcinoma (HCC) have not been fully explored in literature, presumably because HCC skeletal involvement was rarely diagnosed until ...

    Vito Longo, Oronzo Brunetti, Stella D’Oronzo… in Cancer and Metastasis Reviews (2014)